Literature DB >> 7714347

Withdrawal with transdermal fentanyl.

C M Higgs, J Vella-Brincat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7714347     DOI： 10.1016/0885-3924(94)00060-X

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


× No keyword cloud information.
  6 in total

Review 1.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control.

Authors:  W Jeal; P Benfield
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.

Authors:  S Grond; L Radbruch; K A Lehmann
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 4.  Practice guidelines for transdermal opioids in malignant pain.

Authors:  Tracy L Skaer
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.

Authors:  Craig A Kornick; Juan Santiago-Palma; Natalia Moryl; Richard Payne; Eugenie A M T Obbens
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 6.  Transdermal opioids for cancer pain.

Authors:  Tracy L Skaer
Journal:  Health Qual Life Outcomes       Date:  2006-03-31       Impact factor: 3.186
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.